Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy
Takashima, M. E.; Kwon, O.; Ells, Z.; Li, V. R.; Sawicki, C.; Welch Schwartz, R.; Ahn, S. H.; Hyun, M.; Idrissou, M. B.; Berg, T. J.; Clark, P. A.; Lawless, M.; Besemer, A.; Bradshaw, T.; Perlman, S.; Jin, W.; Antonelli, M.; Adeniyi, A. O.; Donnelly Haasch, C.; Chen, T.; Wang, Y.; Kumari, R.; Hernandez, R. T.; Weichert, J.; Belanger, A. P.; Ong, I.; Floberg, J.; Meyer, C.; Kishan, A. U.; Calais, J.; Bednarz, B.; Morris, Z. S.
Show abstract
Radiopharmaceutical therapies (RPT) deliver non-uniform radiation dose in tumors and the impact of this on response is poorly understood. Dose heterogeneity could engender treatment resistance in low dose regions, yet we hypothesize that a broader array of dose-dependent immuno-radiobiological mechanisms in tumor microenvironments (TME) and preservation of immune function in low-dose regions could promote adaptive anti-tumor immunity and response. In murine models, non-uniform lutetium-177 delivering <2.5 Gy to >20 Gy in a TME induced broader immunomodulatory effects and T cell-dependent survival improvement compared to more uniform distributions. Preserving low-dose regions promoted dendritic cell activation and TME infiltration of clonally expanded CD8+ T cells. In three independent cohorts of patients with prostate cancer, heterogeneous tumor dose distribution strongly correlated with improved clinical outcomes. These findings defy expected radiobiological dose-response and define a novel mechanism of action for RPT, supporting clinical investigation of dose distribution for optimizing patient selection and personalized dosing.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Improving SBRT by re-wiring immunosuppressive neutrophils in murine pancreatic ductal adenocarcinoma 94%
- Noninvasive Quantification of Radiation-Induced Lung Injury using a Targeted Molecular Imaging Probe 93%
- FLASH Bragg-peak irradiation with a therapeutic carbon ion beam: first in vivo results 93%
Similar papers in this journal
- Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs 95%
- MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma 93%
- Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models 93%
Similar papers in this journal
- Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition 98%
- Integration of machine learning and genome-scale metabolic modeling identifies multi-omics biomarkers for radiation resistance 94%
- Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC 93%
Similar papers in this journal
- C5aR1 inhibition alleviates cranial radiation-induced cognitive decline 93%
- Modeling Resistance and Recurrence Patterns of Combined Targeted- Chemoradiotherapy Predicts Benefit of Shorter Induction Period 91%
- Spatiotemporal Response Heterogeneity Across Metastatic Lesions Informs Drug Efficacy and Patient Survival in Colorectal Cancer 91%
Similar papers in this journal
- Immune stromal components impede biological effectiveness of carbon ion therapy in a preclinical model of pancreatic ductal adenocarcinoma 96%
- PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity 94%
- Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative Rhabdomyosarcoma 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.